Celebration of postdocs transitions to virtual platform
For the first time ever, the National Postdoctoral Association will celebrate National Postdoc Appreciation Week from September 21-25 as a virtual, collaborative event among multiple institutions. Executive Director Tom Kimbis discusses how the organization is adapting to meet the challenges of COVID-19 to support and advocate for postdocs.  Discuss
Ufovax advances self-assembling nanoparticle COVID-19 vaccine
Vaccine biotechnology company Ufovax announced it will begin phase I clinical trials of its one-component, self-assembling protein nanoparticle (1c-SApNP) SARS-CoV-2 vaccine.
Axon Neuroscience to research COVID-19 vaccine
Clinical-stage biotechnology company Axon Neuroscience plans to start clinical trials of an independently developed, crowdfunded vaccine against COVID-19 called ACvac1.
DIY vaccines are a landmine of public health concerns
A new Science article describes the legal and ethical implications of do-it-yourself (DIY) COVID-19 vaccines.
Are T cells more important than antibodies in COVID-19?
A new study stressed the importance of a multilayered, virus-specific immune response for controlling SARS-CoV-2 during acute COVID-19, with an emphasis on the critical nature of T cells over antibodies during the process. The work was published in Cell on September 16.  Discuss
ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody
ImmunoPrecise and Zymeworks have announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.
Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies
Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.
Could heparin-based therapies be a viable treatment for COVID-19?
Researchers have identified a novel approach to treating SARS-CoV-2 infection, spurred by a new understanding of viral attachment involving a heparan sulfate, a common glycoprotein. The results are presented in a September 14 article published in Cell.  Discuss
AVM Bio to begin trial of COVID-19 immunotherapy
AVM Biotechnology received authorization for an investigational new drug application from the U.S. Food and Drug Administration to evaluate its proprietary drug, AVM0703, in the treatment of acute respiratory distress syndrome mediated by COVID-19 or influenza patients.
Pfizer begins phase I study of COVID-19 drug targeting main protease
Pfizer has begun a phase Ib clinical trial to evaluate the safety of an investigational COVID-19 drug candidate, PF-00835321, that blocks the main protease SARS-CoV-2 enzyme.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter